{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T23:22:28Z","timestamp":1787440948924,"version":"build-2736575974"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/open-government-licence\/version\/3\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1\\u201322-C-0032"],"award-info":[{"award-number":["HDTRA1\\u201322-C-0032"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.biopha.2026.119525","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:58:01Z","timestamp":1780592281000},"page":"119525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The OCTN2 transporter can be targeted by carnitine functionalised non-ionic surfactant vesicles to deliver drugs across the blood-brain barrier"],"prefix":"10.1016","volume":"200","author":[{"given":"Thomas D.","family":"Bateman-Price","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerrie","family":"Hargrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"van Dessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3159-924X","authenticated-orcid":false,"given":"Wendy","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Gill","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5256-7733","authenticated-orcid":false,"given":"Andrew","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad W.","family":"Stratilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Perrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo V.","family":"D\u2019Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119525_bib1","unstructured":"Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 2024, 23:344-381."},{"key":"10.1016\/j.biopha.2026.119525_bib2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s13365-023-01190-8","article-title":"Understanding the link between neurotropic viruses, BBB permeability, and MS pathogenesis","volume":"30","author":"Rani","year":"2024","journal-title":"J. NeuroVirology"},{"key":"10.1016\/j.biopha.2026.119525_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2164-9-289","article-title":"Venezuelan equine encephalitis virus infection causes modulation of inflammatory and immune response genes in mouse brain","volume":"9","author":"Sharma","year":"2008","journal-title":"BMC Genom."},{"key":"10.1016\/j.biopha.2026.119525_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/v11020164","article-title":"Current Understanding of the Molecular Basis of Venezuelan Equine Encephalitis Virus Pathogenesis and Vaccine Development","volume":"11","author":"Sharma","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2026.119525_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003797","article-title":"IRES-Containing VEEV Vaccine Protects Cynomolgus Macaques from IE Venezuelan Equine Encephalitis Virus Aerosol Challenge","volume":"9","author":"Rossi","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.biopha.2026.119525_bib6","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.vetmic.2009.08.023","article-title":"Encephalitic alphaviruses","volume":"140","author":"Zacks","year":"2010","journal-title":"Vet. Microbiol"},{"key":"10.1016\/j.biopha.2026.119525_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/v15020382","article-title":"Sequelae and Animal Modeling of Encephalitic Alphavirus Infections","volume":"15","author":"Reyna","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2026.119525_bib8","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fnins.2024.1514940","article-title":"Neurological manifestations of encephalitic alphaviruses, traumatic brain injuries, and organophosphorus nerve agent exposure","volume":"18","author":"VanderGiessen","year":"2024","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.biopha.2026.119525_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/v15020413","article-title":"Advances in the Development of Small Molecule Antivirals against Equine Encephalitic Viruses","volume":"15","author":"Ogorek","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2026.119525_bib10","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/jac\/dkx224","article-title":"CLL: A compendium of small molecule direct-acting and host-targeting inhibitors as therapies against alphaviruses","volume":"72","author":"Ching","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2026.119525_bib11","doi-asserted-by":"crossref","DOI":"10.15212\/ZOONOSES-2021-0016","article-title":"Venezuelan Equine Encephalitis Virus V3526 Vaccine RNA-Dependent RNA Polymerase Mutants Increase Vaccine Safety Through Restricted Tissue Tropism in a Murine Model","volume":"2","author":"Haines","year":"2022","journal-title":"Zoonoses"},{"key":"10.1016\/j.biopha.2026.119525_bib12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/1743-422X-6-206","article-title":"Development of a novel monoclonal antibody with reactivity to a wide range of Venezuelan equine encephalitis virus strains","volume":"6","author":"O'Brien","year":"2009","journal-title":"Virol. J."},{"key":"10.1016\/j.biopha.2026.119525_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2011.01.010","article-title":"A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus","volume":"90","author":"Goodchild","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.biopha.2026.119525_bib14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41586-021-03909-1","article-title":"Structure of Venezuelan equine encephalitis virus with its receptor LDLRAD3","volume":"598","author":"Ma","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119525_bib15","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41467-024-44872-5","article-title":"LDLR is used as a cell entry receptor by multiple alphaviruses","volume":"15","author":"Zhai","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119525_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112946","article-title":"Entry receptor LDLRAD3 is required for Venezuelan equine encephalitis virus peripheral infection and neurotropism leading to pathogenesis in mice","volume":"42","author":"Kafai","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2026.119525_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02731-19","article-title":"Encephalitic Alphaviruses Exploit Caveola-Mediated Transcytosis at the Blood-Brain Barrier for Central Nervous System Entry","volume":"11","author":"Salimi","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.biopha.2026.119525_bib18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.immuni.2022.04.012","article-title":"Immunological defense of CNS barriers against infections","volume":"55","author":"Ampie","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2026.119525_bib19","article-title":"The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications","volume":"5","author":"Banks","year":"2024","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.biopha.2026.119525_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: Structure, regulation and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119525_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2026.119525_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.brainresbull.2022.09.017","article-title":"The barrier and interface mechanisms of the brain barrier, and brain drug delivery","volume":"190","author":"Zhang","year":"2022","journal-title":"Brain Res Bull."},{"key":"10.1016\/j.biopha.2026.119525_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.biopha.2026.119525_bib24","doi-asserted-by":"crossref","first-page":"200","DOI":"10.14336\/AD.2020.0103","article-title":"The Interstitial System of the Brain in Health and Disease","volume":"11","author":"Shetty","year":"2020","journal-title":"Aging Dis."},{"key":"10.1016\/j.biopha.2026.119525_bib25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.tim.2012.03.009","article-title":"Viral disruption of the blood-brain barrier","volume":"20","author":"Spindler","year":"2012","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.biopha.2026.119525_bib26","unstructured":"Verma A.K., Perlman S.: Unraveling the complexities of neurotropic virus infection and immune evasion. Microbiology and Molecular Biology Reviews, 0:e00185-00123."},{"key":"10.1016\/j.biopha.2026.119525_bib27","series-title":"Human Cerebrospinal Fluid and Cerebrovascular Barrier","first-page":"155","article-title":"Viral Infections of the CNS: Is It All About Breaching Barriers","author":"Schmidt","year":"2025"},{"key":"10.1016\/j.biopha.2026.119525_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","article-title":"The blood-brain barrier: bottleneck in brain drug development","volume":"2","author":"Pardridge","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.biopha.2026.119525_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008157","article-title":"Therapeutic monoclonal antibody treatment protects nonhuman primates from severe Venezuelan equine encephalitis virus disease after aerosol exposure","volume":"15","author":"Burke","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.biopha.2026.119525_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12090837","article-title":"P MK: Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems","volume":"12","author":"Su","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119525_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11020055","article-title":"Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery","volume":"11","author":"Ge","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119525_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cis.2013.11.018","article-title":"Niosomes from 80s to present: the state of the art","volume":"205","author":"Marianecci","year":"2014","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.biopha.2026.119525_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16020223","article-title":"Niosomes: Composition, Formulation Techniques, and Recent Progress as Delivery Systems in Cancer Therapy","volume":"16","author":"Liga","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119525_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106052","article-title":"Functionalized niosomes as a smart delivery device in cancer and fungal infection","volume":"168","author":"Aparajay","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119525_bib35","first-page":"570","article-title":"The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB\/c humoral response to bovine serum albumin","volume":"75","author":"Brewer","year":"1992","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2026.119525_bib36","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jconrel.2020.05.048","article-title":"Glucosamine-NISV delivers antibody across the blood-brain barrier: Optimization for treatment of encephalitic viruses","volume":"324","author":"Woods","year":"2020","journal-title":"J. Control Release"},{"key":"10.1016\/j.biopha.2026.119525_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/703545","article-title":"Receptor-mediated endocytosis and brain delivery of therapeutic biologics","volume":"2013","author":"Xiao","year":"2013","journal-title":"Int J. Cell Biol."},{"key":"10.1016\/j.biopha.2026.119525_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2024.1360302","article-title":"Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria","volume":"4","author":"Haqqani","year":"2024","journal-title":"Front. Drug Deliv."},{"key":"10.1016\/j.biopha.2026.119525_bib39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12987-020-00209-0","article-title":"Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human","volume":"17","author":"Zhang","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.biopha.2026.119525_bib40","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1039\/C6CS00076B","article-title":"Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery","volume":"45","author":"Oller-Salvia","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.biopha.2026.119525_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12970-020-00377-2","article-title":"The bright and the dark sides of L-carnitine supplementation: a systematic review","volume":"17","author":"Sawicka","year":"2020","journal-title":"J. Int Soc. Sports Nutr."},{"key":"10.1016\/j.biopha.2026.119525_bib42","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1046\/j.1471-4159.2001.00621.x","article-title":"Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier","volume":"79","author":"Kido","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2026.119525_bib43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/bdd.371","article-title":"Acetyl-L-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2","volume":"24","author":"Inano","year":"2003","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.biopha.2026.119525_bib44","first-page":"1605","article-title":"L-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation\/carnitine transporter OCTN2","volume":"46","author":"Kou","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119525_bib45","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/0271678X16630991","article-title":"vitro models of the blood-brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use","volume":"36","author":"Helms","year":"2016","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.biopha.2026.119525_bib46","doi-asserted-by":"crossref","DOI":"10.3791\/56277","article-title":"Improved Method for the Establishment of an In Vitro Blood-Brain Barrier Model Based on Porcine Brain Endothelial Cells","author":"Nielsen","year":"2017","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2026.119525_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2010.05.025","article-title":"LRP1 mediates bidirectional transcytosis of amyloid-\u03b2 across the blood-brain barrier","volume":"32","author":"Pflanzner","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.biopha.2026.119525_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/cells12182312","article-title":"The Chemical Inhibitors of Endocytosis: From Mechanisms to Potential Clinical Applications","volume":"12","author":"Szewczyk-Roszczenko","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119525_bib49","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0300-9629(96)00414-8","article-title":"Effect of Temperature on Endocytosis and Intracellular Transport in the Cell Line SHK-1 Derived from Salmon Head Kidney","volume":"117","author":"Rode","year":"1997","journal-title":"Comparative Biochemistry Physiology Part A Physiology"},{"key":"10.1016\/j.biopha.2026.119525_bib50","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12950-024-00419-5","article-title":"Non-ionic surfactant vesicles exert anti-inflammatory effects through inhibition of NF\u03baB","volume":"21","author":"McGahon","year":"2024","journal-title":"J. Inflamm."},{"key":"10.1016\/j.biopha.2026.119525_bib51","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/brain\/awaf068","article-title":"The blood\u2013brain barrier: a help and a hindrance","volume":"148","author":"Rust","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2026.119525_bib52","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood-brain barrier active efflux transporters: ATP-binding cassette gene family","volume":"2","author":"L\u00f6scher","year":"2005","journal-title":"NeuroRx"},{"key":"10.1016\/j.biopha.2026.119525_bib53","article-title":"Recent progress on nanotechnologies for enhancing blood-brain barrier permeability","volume":"3","author":"Liu","year":"2025","journal-title":"Smart Mol."},{"key":"10.1016\/j.biopha.2026.119525_bib54","doi-asserted-by":"crossref","first-page":"32606","DOI":"10.1021\/acsomega.5c02206","article-title":"Nanotherapeutic Strategies for Overcoming the Blood-Brain Barrier: Applications in Disease Modeling and Drug Delivery","volume":"10","author":"Kirit","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.biopha.2026.119525_bib55","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1021\/acsnano.3c10674","article-title":"Functionalized Nanomaterials Capable of Crossing the Blood\u2013Brain Barrier","volume":"18","author":"Zha","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.biopha.2026.119525_bib56","article-title":"Crossing the blood-brain barrier: nanoparticle-based strategies for neurodegenerative disease therapy","author":"Haro-Mart\u00ednez","year":"2025","journal-title":"Drug Deliv. Transl. Res"},{"key":"10.1016\/j.biopha.2026.119525_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2012.06.057","article-title":"Establishment of a simplified in vitro porcine blood\u2013brain barrier model with high transendothelial electrical resistance","volume":"1521","author":"Patabendige","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.biopha.2026.119525_bib58","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/jps.23575","article-title":"Quantitative atlas of blood\u2013brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset","volume":"102","author":"Hoshi","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119525_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134765","article-title":"A Triple Culture Model of the Blood-Brain Barrier Using Porcine Brain Endothelial cells, Astrocytes and Pericytes","volume":"10","author":"Thomsen","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.biopha.2026.119525_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236770","article-title":"The blood-brain barrier studied in vitro across species","volume":"16","author":"Thomsen","year":"2021","journal-title":"PLOS ONE"},{"key":"10.1016\/j.biopha.2026.119525_bib61","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tins.2013.07.001","article-title":"Sugar for the brain: the role of glucose in physiological and pathological brain function","volume":"36","author":"Mergenthaler","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.biopha.2026.119525_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10020057","article-title":"Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems","volume":"10","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119525_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2023.107124","article-title":"Palmitoylation modifies transmembrane adaptor protein PAG for ordered lipid environment: A molecular dynamics simulation study","volume":"304","author":"Saija","year":"2024","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.biopha.2026.119525_bib64","doi-asserted-by":"crossref","first-page":"41471","DOI":"10.1039\/D0RA07161G","article-title":"A brain glioma gene delivery strategy by angiopep-2 and TAT-modified magnetic lipid-polymer hybrid nanoparticles","volume":"10","author":"Qiao","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.biopha.2026.119525_bib65","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40005-023-00657-4","article-title":"Transferrin modified PEG\u2013PLGA nanoparticles: highly effective notoginsenoside R1 formulations for the treatment of ulcerative colitis","volume":"54","author":"Zhou","year":"2024","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.biopha.2026.119525_bib66","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/ma11020324","article-title":"Fe3O4 Nanoparticles in Targeted Drug\/Gene Delivery Systems","volume":"11","author":"Shen","year":"2018","journal-title":"Materials"},{"key":"10.1016\/j.biopha.2026.119525_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc7031","article-title":"Blood-brain barrier\u2013penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy","volume":"6","author":"Zhou","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2026.119525_bib68","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1021\/acschemneuro.0c00076","article-title":"GLUT-1: An Effective Target To Deliver Brain-Derived Neurotrophic Factor Gene Across the Blood Brain Barrier","volume":"11","author":"Arora","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2026.119525_bib69","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2133\/dmpk.DMPK-13-RG-058","article-title":"Functional expression of organic cation\/carnitine transporter 2 (OCTN2\/SLC22A5) in human brain capillary endothelial cell line hCMEC\/D3, a human blood-brain barrier model","volume":"29","author":"Okura","year":"2014","journal-title":"Drug Metab. Pharm."},{"key":"10.1016\/j.biopha.2026.119525_bib70","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1471-4159.2006.03757.x","article-title":"Functional expression of the organic cation\/carnitine transporter 2 in rat astrocytes","volume":"97","author":"Inazu","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2026.119525_bib71","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1080\/10717544.2017.1377316","article-title":"Dual targeting of l-carnitine-conjugated nanoparticles to OCTN2 and ATB(0,+) to deliver chemotherapeutic agents for colon cancer therapy","volume":"24","author":"Kou","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2026.119525_bib72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3892\/etm.2012.556","article-title":"Carnitine-induced senescence in glioblastoma cells","volume":"4","author":"Yamada","year":"2012","journal-title":"Exp. Ther. Med"},{"key":"10.1016\/j.biopha.2026.119525_bib73","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/0008-5472.CAN-19-0638","article-title":"Localized Metabolomic Gradients in Patient-Derived Xenograft Models of Glioblastoma","volume":"80","author":"Randall","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119525_bib74","article-title":"Optimizing Angiopep-2 Density on Polymeric Nanoparticles for Enhanced Blood\u2013Brain Barrier Penetration and Glioblastoma Targeting: Insights From In Vitro and In Vivo Experiments","volume":"35","author":"Zhang","year":"2025","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.biopha.2026.119525_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12010072","article-title":"PLGA-PEG-ANG-2 Nanoparticles for Blood-Brain Barrier Crossing: Proof-of-Concept Study","volume":"12","author":"Hoyos-Ceballos","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119525_bib76","doi-asserted-by":"crossref","first-page":"12161","DOI":"10.1021\/acsami.3c14709","article-title":"Angiopep-2-Functionalized Lipid Cubosomes for Blood\u2013Brain Barrier Crossing and Glioblastoma Treatment","volume":"16","author":"Cai","year":"2024","journal-title":"ACS Appl. Mater. & Interfaces"},{"key":"10.1016\/j.biopha.2026.119525_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102237","article-title":"Blood-Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles","volume":"14","author":"Thomsen","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119525_bib78","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1039\/C9NR08784B","article-title":"Impact of plasma concentration of transferrin on targeting capacity of nanoparticles","volume":"12","author":"Sepand","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2026.119525_bib79","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jconrel.2019.01.005","article-title":"Modulating the antibody density changes the uptake and transport at the blood-brain barrier of both transferrin receptor-targeted gold nanoparticles and liposomal cargo","volume":"295","author":"Johnsen","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119525_bib80","article-title":"Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease","volume":"35","author":"Sela","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biopha.2026.119525_bib81","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1471-4159.2007.05024.x","article-title":"Localization of organic cation\/carnitine transporter (OCTN2) in cells forming the blood-brain barrier","volume":"104","author":"Miecz","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2026.119525_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102340","article-title":"l-Type amino acid transporter 1-targeting nanoparticles for antisense oligonucleotide delivery to the CNS","volume":"35","author":"Lim","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2026.119525_bib83","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jconrel.2016.10.031","article-title":"Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB0,+-mediated tumor targeting of liposomes for docetaxel delivery for hepatocarcinoma therapy","volume":"243","author":"Luo","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119525_bib84","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/17425247.2020.1723544","article-title":"Endocytosis of ATB0,+(SLC6A14)-targeted liposomes for drug delivery and its therapeutic application for pancreatic cancer","volume":"17","author":"Kou","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biopha.2026.119525_bib85","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1002\/adma.201101899","article-title":"Choline-Derivate-Modified Nanoparticles for Brain-Targeting Gene Delivery","volume":"23","author":"Li","year":"2011","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biopha.2026.119525_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28031151","article-title":"Transporter-Mediated Drug Delivery","volume":"28","author":"Gyimesi","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119525_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114185","article-title":"L-carnitine modified nanoparticles target the OCTN2 transporter to improve the oral absorption of jujuboside B","volume":"196","author":"Li","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.biopha.2026.119525_bib88","first-page":"120","article-title":"Unraveling GLUT-mediated transcytosis pathway of glycosylated nanodisks","volume":"16","author":"Wang","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119525_bib89","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0014-5793(02)03058-2","article-title":"GLUT2 is a high affinity glucosamine transporter","volume":"524","author":"Uldry","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2026.119525_bib90","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.biomaterials.2013.09.094","article-title":"Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment","volume":"35","author":"Jiang","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119525_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2026.119525_bib92","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.meegid.2012.02.003","article-title":"pH-dependent entry of chikungunya virus into Aedes albopictus cells","volume":"12","author":"Gay","year":"2012","journal-title":"Infect. Genet Evol."},{"key":"10.1016\/j.biopha.2026.119525_bib93","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.omtn.2023.07.019","article-title":"Chloroquine and cytosolic galectins affect endosomal escape of antisense oligonucleotides after Stabilin-mediated endocytosis","volume":"33","author":"Pandey","year":"2023","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"10.1016\/j.biopha.2026.119525_bib94","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20131660","article-title":"Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants","volume":"211","author":"Bien-Ly","year":"2014","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.biopha.2026.119525_bib95","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1582-4934.2009.00754.x","article-title":"Endocytosis via caveolae: alternative pathway with distinct cellular compartments to avoid lysosomal degradation?","volume":"13","author":"Kiss","year":"2009","journal-title":"J. Cell Mol. Med"},{"key":"10.1016\/j.biopha.2026.119525_bib96","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jconrel.2020.10.049","article-title":"Macropinocytosis as a cell entry route for peptide-functionalized and bystander nanoparticles","volume":"329","author":"Li","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2026.119525_bib97","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1177\/0271678X241240843","article-title":"Alterations of the blood-brain barrier during aging","volume":"44","author":"Cao","year":"2024","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.biopha.2026.119525_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/biom15040456","article-title":"Caveolae-Mediated Transcytosis and Its Role in Neurological Disorders","volume":"15","author":"Yang","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2026.119525_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32033-w","article-title":"Lipid-Coated Mesoporous Silica Nanoparticles for the Delivery of the ML336 Antiviral to Inhibit Encephalitic Alphavirus Infection","volume":"8","author":"LaBauve","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119525_bib100","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1023\/A:1026422915326","article-title":"Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting","volume":"17","author":"Dufes","year":"2000","journal-title":"Pharm. Res."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226005615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226005615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:51:31Z","timestamp":1787439091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226005615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":100,"alternative-id":["S0753332226005615"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119525","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The OCTN2 transporter can be targeted by carnitine functionalised non-ionic surfactant vesicles to deliver drugs across the blood-brain barrier","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119525"}}